Clinical trial
Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma
NCT00486564 · University of Vermont, Other · Completed
Key facts
| NCT number | NCT00486564 |
|---|---|
| Title | Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma |
| Official title | A Phase I Trial of Nifurtimox for Relapsed or Refractory Neuroblastoma |
| Lead sponsor | University of Vermont, Other |
| Collaborators | St. Louis University |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Drug |
| Interventions | Nifurtimox |
| Enrollment | 20 |
| Start date | Nov 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Jun 1, 2009 |
| First posted | Jun 14, 2007 |
| Last update posted | Oct 23, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: